tiprankstipranks
Trending News
More News >

Invion Reports Positive Trial Results for Skin Cancer Treatment

Story Highlights
  • Invion focuses on developing PDT treatments for non-melanoma skin cancer.
  • The trial showed no adverse events and significant lesion reduction, boosting Invion’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Invion Reports Positive Trial Results for Skin Cancer Treatment

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Invion ( (AU:IVX) ) is now available.

Invion Limited has addressed a query from the ASX regarding the timing of its cleansing notice related to its Phase I/II trial for non-melanoma skin cancer. The company confirmed that the trial showed no adverse events and that the treatment was well tolerated with observable reductions in lesion size, marking a significant advancement over existing PDT treatments. This development is crucial for Invion’s market positioning as it demonstrates the potential efficacy and safety of its treatment, which could enhance investor confidence and stakeholder interest.

More about Invion

Invion Limited operates in the biotechnology industry, focusing on the development of Photodynamic Therapy (PDT) treatments for non-melanoma skin cancer (NMSC). The company is engaged in clinical trials to advance its therapeutic solutions in this niche market.

Average Trading Volume: 102,006

Technical Sentiment Signal: Sell

Current Market Cap: A$10.17M

See more data about IVX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1